The metabolic fate of the Alzheimer 8/A4
The leading cause of dementia and the fourth leading cause of death in the developed world is Alzheimer disease (AD), which afflicts an estimated 10%o of the population over 65 years of age in the United States (1) . The disease manifests itself as insidious memory loss, cognitive decline, and personality changes that result in loss of functional ability over the course of a decade. In their debilitated state, patients usually retain only vegetative neurologic function and succumb to secondary infections (2) .
AD is characterized by certain neuropathological lesions, including intracellular neurofibrillary tangles and extracellular parenchymal and cerebrovascular amyloid (3) . The principal component of the amyloid deposits is a protein designated B/A4 amyloid (4, 5) , an =4-kDa polypeptide arising from cleavage of the amyloid precursor protein (APP) (6) (7) (8) (9) . APP exists as three major transmembrane isoforms (APP695, APP751, and APP770) that result from alternative splicing of a single primary transcript (Fig. 1A) (7, (10) (11) (12) . Secretory processing of APP (13) leads to cleavage within the /A4 domain ("normal" cleavage) and precludes amyloidogenesis (14, 15) . The biochemical defect responsible for amyloid production in AD might, therefore, involve either a deficiency in this proteolytic pathway or excessive activity of an alternative pathway. It is noteworthy that two types of inherited cerebral amyloidoses-hereditary cerebral hemorrhage with amyloidosis (Dutch type) and familial early-onset AD-are associated with mutations in the coding sequence of APP near the f3/A4-amyloid domain (16) (17) (18) (19) .
Although the events leading to abnormal APP processing and amyloidosis are not known, elucidation of normal processing pathways may provide insights into AD pathogenesis. Cultured mammalian cells provide a readily accessible and well-characterized system for studies of protein trafficking. In the present investigation, we have examined the intracellular trafficking and processing of APP by [35S]methionine' pulse-labeling of PC12 neuroendocrine cells in the presence of pharmacologic agents known to affect the function of specific intracellular organelles.
MATERIALS AND METHODS
Chloroquine was purchased from Sigma, monensin was purchased from Calbiochem, and brefeldin A was purchased from Epicentre Technologies (Madison, WI). Ascites fluid from mice injected intraperitoneally with hybridoma cells producing the anti-N-terminal APP monoclonal antibody 22C11 (13) was the kind gift of T. V. Ramabhadran (our laboratory) and S. S. Sisodia (The Johns Hopkins University School of Medicine, Baltimore). Affinity-purified rabbit anti-C-terminal APP antibody, here termed 369A, has been described (20 ,ug/ml) were examined, drug was added at the start of the preincubation period and was present throughout the pulsechase period. Cell viability remained unchanged throughout the chase period as determined by trypan blue exclusion.
At the end of the chase period (0-8 h), cells were rapidly pelleted and the medium was removed. Cells and media were treated with 1% SDS, boiled 5 min, sonicated (cell lysates only), and centrifuged at 10,000 x g for 10 min. After dilution with an equal volume of neutralization buffer [6% (vol/vol) Nonidet P40/200 mM Tris'HCI, pH 7.4/300 mM NaCl/10 mM EDTA/4 mM NaN3], supernatants were incubated at 4°C with antibody 22C11 overnight (medium) or with antibody 369A for 2 h (cell lysates). Immune complexes were precipitated with 200 ,ul (vol/vol) of agarose-coupled antimouse or anti-rabbit antibody or with protein A-Sepharose, and the pellets were washed three times with 1 ml of Tris-buffered saline (100 mM Tris-HCI, pH 7.4/150 mM NaCI/2 mM NaN3).
Samples were boiled in 100 .ul of sample buffer [62.5 mM Tris HCI, pH 6.8/2% (wt/vol) SDS/5% (vol/vol) 2-mercaptoethanol/10% (wt/vol) sucrose] and separated by SDS/ PAGE on 4-15% gradient gels (cell lysates) or 6% gels (medium). Gels were treated for fluorography with enhancer solution (Entensify; NEN Research Products), dried, and exposed to preflashed x-ray film at -70°C. Proteins were quantitated by scanning densitometry (since immature APP751 and APP770 isoforms could not be resolved by densitometry, they were reported together as immature APPKPI, where KPI is Kunitz serine protease inhibitor, a domain common to both APP751 and APP770). Values were corrected for length of exposure time, signal decay, and the number of methionine residues in individual APP species and normalized to the total APP holoprotein present in untreated cells at the start of the chase period (100 relative units). It should be noted that synthesis of labeled protein continued after the start of the chase and, therefore, that the values for the recovery of mature APP, secreted APP, and the C-terminal APP fragment are overestimated in absolute terms but accurate in relative terms.
RESULTS
Identification of APP Species. Immunoprecipitates from metabolically labeled PC12 cells using an antibody directed against the C terminus of APP contained six protein bands of molecular masses 106, 112, 116, 125, 139, and 146 kDa (Fig.  1B) . The three lower bands have previously been designated as immature APP695, APP751, and APP770 holoprotein, respectively, and the three higher bands have been shown to correspond to mature APP isoforms, in which the proteins are fully N-and 0-glycosylated and sulfated (13, 20) . Using agents that inhibit conversion of immature to mature APP (see below) and a monoclonal antibody directed against the KPI domain of isoforms APP751 and APP770 (21), and based upon the lengths of the individual isoforms, we confirmed the protein band assignment.
Also present in the immunoprecipitated cell lysates was a protein of molecular mass 16.3 kDal (Fig. 1C) . This truncated APP fragment represents the C-terminal product with a predicted molecular mass of9.2 kDa resulting from the normal intraamyloid cleavage of APP (15) , as determined by its protein sequencing (our unpublished observations), and was previously referred to as a 15-kDa peptide (20) . Immunoprecipitation of the seven APP species with the C-terminal antibody could be abolished by preincubation of antibody with peptide corresponding to APP-(645-694) (APP695 numbering system).
Immunoprecipitates of culture medium with antibody directed against the N terminus of APP contained three protein bands of molecular masses 109, 123, and 129 kDa (Fig. 1D) . The two higher bands could also be immunoprecipitated with the antibody directed against the KPI domain insert. These proteins were not immunoprecipitated with the anti-Cterminal antibody. Since the difference in masses between the mature APP holoproteins (from which the secreted forms are believed to arise; see below) and the APP C-terminal fragment closely agree with the masses of the secreted forms, we conclude that they are the secreted fragments of APP695, APP751, and APP770. No secreted forms were recovered from cell lysates when supernatants from immunoprecipitations with anti-C-terminal antibody were reincubated with anti-Nterminal antibody.
Effect of Chloroquine on Acidic Organelles. Since some evidence for lysosomal APP processing has been reported (22, 23) , we examined the effects of chloroquine on APP metabolism. Chloroquine is a weak base that is taken up by cells where it is concentrated in and neutralizes acidic organelles such as lysosomes (24, 25 these organelles results in the inhibition of their aciddependent hydrolases. Chloroquine neutralization of acidic organelles in the PC12 cells was confirmed by fluorescence microscopy after acridine orange treatment (26, 27) in the absence and presence of chloroquine (data not shown).
Effect ofChloroquine on APP Maturation. At the start ofthe chase period nearly all of the labeled APP was in the form of immature holoprotein (Fig. 1B) . Within =15 min, half of the immature APP was converted to mature APP (Fig. 2) . No difference in the rate of maturation was found between APP695 and APPKPI. Chloroquine had virtually no effect on APP maturation (Fig. 2) .
Effect of Chloroquine on Mature APP Holoprotein. In untreated cells, the level of mature APP holoprotein rose to a maximum by 30 min, corresponding to conversion of immature APP to its fully glycosylated and sulfated forms (Fig. 3) (13) . The amount of mature APP isoforms then decreased with a half-life of =90 min. At 8 h of chase, the levels of mature APP isoforms had returned to their starting levels. We attribute the decrease of APP levels with time to conversion of mature APP to secreted forms, as well as to proteolytic degradation unassociated with secretion.
When cells were treated with chloroquine, a significant effect on turnover of mature APP was observed (Fig. 3) . The levels of mature APP holoprotein peaked 30 min later than in control samples. APP isoforms were present at approximately twice the levels found in untreated cells, from 1 to 8 h of chase. The magnitude of the chloroquine effect was the same for the different APP isoforms.
Effect of Chloroquine on APP Secretion. In untreated cells, after a brief lag, levels of secreted APP isoforms rose linearly from 0 to 4 h of chase (Fig. 4) . Little or no further increase in APP secretion was observed up to 8 h of chase. Maximal levels of secreted APP represented -14% of total APP present at the start of chase. When cells were treated with chloroquine, virtually no change in the rate of APP secretion was found for any APP isoform (Fig. 4) . The maximal level of APP secretion was approximately the same for control and chloroquine-treated samples at 4 h. At 6 and 8 h of chase, there tended to be a small decrease in recovery of secreted APP. This decrease was attributable to proteolytic degradation in the medium, since recovery of secreted APP in 4-h chase medium incubated in the absence of cells decreased with time. Chloroquine was found to promote the proteolysis in the medium to an extent comparable to that shown in Fig. 4 (data not  shown) .
Effect of Chloroquine on the APP C-Terminal Fragment. In untreated cells, the level of the APP C-terminal fragment reached a maximum at 1 h of chase and decreased slowly thereafter (Fig. 5) . Since mature APP holoprotein was still being degraded and secreted APP was still being produced at this time, we conclude that the C-terminal APP fragment is subject to further proteolytic degradation.
Chloroquine had a marked effect on recovery of the C-terminal fragment. At all time points from 2 to 8 h, recovery of the 16.3-kDa APP fragment was significantly greater from chloroquine-treated than from untreated cells. These data are consistent with the proposal that the APP C-terminal frag- ment is further degraded in an acidic organelle following its generation by intraamyloid cleavage.
The maximal level of recovery of the C-terminal APP fragment was equivalent to 9%o of APP holoprotein present at the start of chase and =60% of secreted APP present at 4 h of chase. In the presence of chloroquine, these values were 13% and 92%, respectively.
Effects APP maturation (Fig. 6A) . Furthermore, no secreted APP fragment (Fig. 6B ) or 16.3-kDa APP fragment (data not shown) was recovered.
The fungal product brefeldin A produces an apparent dissolution of the Golgi complex by causing resorption of the Golgi into the endoplasmic reticulum and fusion of the trans-Golgi network with the endosomal system (29) . When cells were treated with brefeldin A from the start of the preincubation period, normal APP maturation was inhibited (Fig. 6A) . Instead, a broad band of molecular mass greater than that of immature APP but less than that of mature APP was observed. As Golgi enzymes, though relocated to the endoplasmic reticulum, can still function in the presence of brefeldin A (30), we suggest that APP underwent abnormal glycosylation. Brefeldin A also prevented secretion of APP fragments (Fig. 6B) and production of the C-terminal fragment (data not shown).
The data obtained with monensin and brefeldin A suggest that partially glycosylated APP (13) passes through the cisand medial-Golgi and then reaches the trans-Golgi, where final glycosylation and sulfation (31) occur. Both monensin and brefeldin A inhibited complete APP maturation and prevent APP proteolysis and secretion. This indicates that proteolysis and secretory cleavage occur in the distal Golgi or a subsequent compartment. These results appear to exclude the possibility that APP secretory cleavage might occur in the endoplasmic reticulum or proximal Golgi. APP and an APP C-terminal fragment but has virtually no effect on APP maturation or secretion. In the present study, the APP fragments released into the medium represented =144% of the APP holoprotein present at the start of the chase. Recovery of the APP C-terminal fragment in the presence of chloroquine represented 13% of total APP holoprotein but 92% of total secreted APP. The quantitative agreement between the production of secreted APP fragments and the C-terminal APP firgment suggests that the 16.3-kDa fragment arising by intraamyloid cleavage results almost entirely from the secretory pathway. The C-terminal fragment would then be sorted for further proteolysis in acidic organelles such as lysosomes. In support of this possibility, chloroquine caused increased recovery of the 16.3-kDa peptide; since secretion was unchanged by chloroquine, the increased recovery of the C-terminal fragment is unlikely to be due to enhanced production but rather to decreased degradation.
The chloroquine-sensitive proteolytic turnover of APP presumably takes place in an acidic compartment such as endosomes or lysosomes. The specific cleavage of APP to produce a secreted species, on the other hand, was not sensitive to chloroquine, suggesting that this event occurs at a different cellular location. Quantitatively, our results suggest that intraamyloid cleavage of APP and the associated secretion of N-terminal APP fragments represent a minor portion of total APP metabolism and that most APP molecules are degraded along a separate subcellular route of trafficking. The identification of the cellular locations of the enzymes responsible for these distinct proteolytic pathways should facilitate the development of drug therapies directed at altering APP metabolism and treating AD.
